IL116931A - Use of N2-¬¬2-¬4-(2-substituted-benzimidazol-L-YL(and imidazo¬4,5-b¾¬pyridin-1-YL)methyl)phenyl¾-cyclohexyl¾-carbonyl¾glycinamide derivatives in the preparation of pharmaceutical compositions for treatment of restenosis certain such novel compounds and their preparation - Google Patents

Use of N2-¬¬2-¬4-(2-substituted-benzimidazol-L-YL(and imidazo¬4,5-b¾¬pyridin-1-YL)methyl)phenyl¾-cyclohexyl¾-carbonyl¾glycinamide derivatives in the preparation of pharmaceutical compositions for treatment of restenosis certain such novel compounds and their preparation

Info

Publication number
IL116931A
IL116931A IL11693196A IL11693196A IL116931A IL 116931 A IL116931 A IL 116931A IL 11693196 A IL11693196 A IL 11693196A IL 11693196 A IL11693196 A IL 11693196A IL 116931 A IL116931 A IL 116931A
Authority
IL
Israel
Prior art keywords
preparation
benzimidazol
imidazo
restenosis
pyridin
Prior art date
Application number
IL11693196A
Other languages
English (en)
Other versions
IL116931A0 (en
Original Assignee
Bayer Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Bayer Ag filed Critical Bayer Ag
Publication of IL116931A0 publication Critical patent/IL116931A0/xx
Publication of IL116931A publication Critical patent/IL116931A/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4184—1,3-Diazoles condensed with carbocyclic rings, e.g. benzimidazoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/437—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a five-membered ring having nitrogen as a ring hetero atom, e.g. indolizine, beta-carboline
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/08—Radicals containing only hydrogen and carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/06—Benzimidazoles; Hydrogenated benzimidazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D235/14—Radicals substituted by nitrogen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
IL11693196A 1995-02-01 1996-01-29 Use of N2-¬¬2-¬4-(2-substituted-benzimidazol-L-YL(and imidazo¬4,5-b¾¬pyridin-1-YL)methyl)phenyl¾-cyclohexyl¾-carbonyl¾glycinamide derivatives in the preparation of pharmaceutical compositions for treatment of restenosis certain such novel compounds and their preparation IL116931A (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19503160A DE19503160A1 (de) 1995-02-01 1995-02-01 Verwendung von Phenylcyclohexylcarbonsäureamiden

Publications (2)

Publication Number Publication Date
IL116931A0 IL116931A0 (en) 1996-05-14
IL116931A true IL116931A (en) 2000-06-01

Family

ID=7752849

Family Applications (1)

Application Number Title Priority Date Filing Date
IL11693196A IL116931A (en) 1995-02-01 1996-01-29 Use of N2-¬¬2-¬4-(2-substituted-benzimidazol-L-YL(and imidazo¬4,5-b¾¬pyridin-1-YL)methyl)phenyl¾-cyclohexyl¾-carbonyl¾glycinamide derivatives in the preparation of pharmaceutical compositions for treatment of restenosis certain such novel compounds and their preparation

Country Status (31)

Country Link
US (1) US5935983A (es)
EP (1) EP0725064A1 (es)
JP (1) JPH08253453A (es)
KR (1) KR960031442A (es)
CN (1) CN1137380A (es)
AR (1) AR002272A1 (es)
AU (1) AU710235B2 (es)
BG (2) BG63044B1 (es)
CA (1) CA2168317A1 (es)
CZ (1) CZ29196A3 (es)
DE (1) DE19503160A1 (es)
DZ (1) DZ1986A1 (es)
EE (1) EE9600023A (es)
FI (1) FI960425A (es)
HR (1) HRP960017A2 (es)
HU (1) HUP9600227A3 (es)
IL (1) IL116931A (es)
MA (1) MA23794A1 (es)
NO (1) NO309841B1 (es)
NZ (1) NZ280905A (es)
PL (1) PL312546A1 (es)
RO (1) RO117256B1 (es)
RU (1) RU2158261C2 (es)
SG (1) SG42329A1 (es)
SK (1) SK13796A3 (es)
SV (1) SV1996000008A (es)
TN (1) TNSN96016A1 (es)
TW (1) TW448176B (es)
UA (1) UA35623C2 (es)
YU (1) YU5896A (es)
ZA (1) ZA96725B (es)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6911462B2 (en) * 1998-05-22 2005-06-28 Avanir Pharmaceuticals Benzimidazole compounds for regulating IgE
DE19924818A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäureamide
DE19924819A1 (de) * 1999-05-29 2000-11-30 Bayer Ag Substituierte Phenylcyclohexancarbonsäurebenzylamid (Adenosinaufnahmeinhibitoren)
DE60221804T2 (de) * 2001-03-12 2008-05-15 Avanir Pharmaceuticals, San Diego Benzimidazolderivate zur ige-modulierung und zellproliferationshemmung
DE10150310A1 (de) * 2001-10-11 2003-04-24 Bayer Ag Substituierte Piperazincyclohexancarbonsäureamide und ihre Verwendung
US6934951B2 (en) 2002-01-17 2005-08-23 Intel Corporation Parallel processor with functional pipeline providing programming engines by supporting multiple contexts and critical section
TW200304820A (en) * 2002-03-25 2003-10-16 Avanir Pharmaceuticals Use of benzimidazole analogs in the treatment of cell proliferation
TW200400040A (en) * 2002-05-17 2004-01-01 Wyeth Corp Hormone replacement therapy
AU2003270426A1 (en) 2002-09-12 2004-04-30 Avanir Pharmaceuticals PHENYL-INDOLE COMPOUNDS FOR MODULATING IgE AND INHIBITING CELLULAR PROLIFERATION
TWI276631B (en) * 2002-09-12 2007-03-21 Avanir Pharmaceuticals Phenyl-aza-benzimidazole compounds for modulating IgE and inhibiting cellular proliferation
EP1651198A2 (en) * 2003-08-08 2006-05-03 Avanir Pharmaceuticals Selective pharmacologic inhibition of protein trafficking and related methods of treating human diseases

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE4226109A1 (de) * 1992-08-07 1994-02-10 Bayer Ag Verwendung von ASS zur Hemmung von Plaquebildung
DE4304455A1 (de) * 1993-02-15 1994-08-18 Bayer Ag Heterocyclisch substituierte Phenyl-cyclohexan-carbonsäurederivate
US5358959A (en) * 1993-02-18 1994-10-25 President And Fellows Of Harvard University Methods for treating arteriosclerosis
DE4401893A1 (de) * 1994-01-24 1995-07-27 Bayer Ag Substituierte Arylharnstoffe

Also Published As

Publication number Publication date
CZ29196A3 (en) 1996-08-14
DE19503160A1 (de) 1996-08-08
RO117256B1 (ro) 2001-12-28
CA2168317A1 (en) 1996-08-02
PL312546A1 (en) 1996-08-05
SV1996000008A (es) 1996-11-04
SG42329A1 (en) 1997-08-15
AR002272A1 (es) 1998-03-11
NO960414L (no) 1996-08-02
SK13796A3 (en) 1996-10-02
RU2158261C2 (ru) 2000-10-27
US5935983A (en) 1999-08-10
JPH08253453A (ja) 1996-10-01
YU5896A (sh) 1998-12-23
EE9600023A (et) 1996-08-15
UA35623C2 (uk) 2001-04-16
ZA96725B (en) 1996-08-20
IL116931A0 (en) 1996-05-14
TW448176B (en) 2001-08-01
HUP9600227A2 (en) 1996-12-30
EP0725064A1 (de) 1996-08-07
AU710235B2 (en) 1999-09-16
MA23794A1 (fr) 1996-10-01
HU9600227D0 (en) 1996-03-28
FI960425A (fi) 1996-08-02
BG100326A (bg) 1996-08-30
TNSN96016A1 (fr) 2005-03-15
BG63044B1 (bg) 2001-02-28
BG103820A (bg) 2001-09-28
AU4224096A (en) 1996-08-08
HRP960017A2 (en) 1997-12-31
NO309841B1 (no) 2001-04-09
CN1137380A (zh) 1996-12-11
KR960031442A (ko) 1996-09-17
HUP9600227A3 (en) 2000-03-28
NZ280905A (en) 1996-12-20
NO960414D0 (no) 1996-01-31
DZ1986A1 (fr) 2002-10-15
FI960425A0 (fi) 1996-01-30

Similar Documents

Publication Publication Date Title
HUP0203450A3 (en) Pyrazolo '4,3-d! pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing them and their use
HUP0104867A3 (en) Heterocyclic compounds useful in the treatment of inflammatory diseases, process for their preparation, pharmaceutical compositions comprising thereof and their use
HUP0202103A2 (en) 8-phenyl-6,9-dihydro-[1,2,4]triazolo[3,4-i]purin-5-one derivatives, their use, pharmaceutical compositions containing them, process for the preparation of the compounds and intermediates
HUP0100202A3 (en) Novel triazolo[4,5-d]pyrimidine derivatives, process for their preparation, their use and pharmaceutical compositions containing them
HUP9801587A3 (en) 5h-thiazolo[3,2-a]pyrimidine derivatives, process for their preparation, intermediates, use of the compounds and pharmaceutical compositions containing them
HUP0203542A3 (en) 3(5)-amino-pyrazole derivatives, process for their preparation, their use and pharmaceutical compositions containing the same
HUP0200450A3 (en) Cephen derivatives containing an imidazo[4,5-b]pyridiniummethyl moiety, process for their preparation and pharmaceutical compositions of the same
HUP9801602A3 (en) Imidazo[1,2-a]pyridine derivatives, process for their production, pharmaceutical compositions and use thereof
HUP0004333A3 (en) Novel triazolo [4,5-d] pyrimidine derivatives, process for their preparation and pharmaceutical compositions containing thereof
HUP0100179A3 (en) Imidazopyrimidine and imidazopyridine derivatives and pharmaceutical compositions thereof
HUP9800138A3 (en) 8-substituted-1,3,8-triaza-spiro [4,5]-decan-4-on derivatives, process for producing them, pharmaceutical compositions containing the same and their use
HUP0203142A3 (en) Benzodiazepine derivatives, process for preparation of the compounds, pharmaceutical compositions containing them and their use
HUP0001607A3 (en) Thienopyrimidine derivatives, pharmaceutical compositions containing them, process for their preparation and use of the compounds
AP9901556A0 (en) Sulpponamide derivatives process for their preparation and their use as medicaments
HUP0000720A3 (en) Imidazo [1,2-a] pyridine derivatives, process for their preparation, pharmaceutical formulation containing them and their use
HUP0001508A3 (en) 4-arylmethylene-2-imino-2,3-dihydrothiazole derivatives, their use, process for the preparation thereof and pharmaceutical compositions containing them
HUP9900974A3 (en) Heterocycle-condensed morphinoid derivatives, process for the preparation thereof, their use and pharmaceutical compositions containing them
HUP0002902A3 (en) 3-substituted 3,4 dyhydro-thieno[2,3-d]pyrimidine derivatives and their use for the preparation of pharmaceutical compositions
HUP0003826A3 (en) Novel triazolo [4,5-b] pyrimidine derivatives, process for their preparation and pharmaceutical compositions thereof
NZ322197A (en) Pyrido[2,3-d] pyrimidine derivatives and pharmaceutical compositions thereof
HUP0000664A3 (en) Azinyloxy, and phenoxy-diaryl-carboxylic acid derivatives, their preparation and use of them for producing pharmaceutical compositions
HUP0100170A3 (en) N-benzyl-3-indenylacetamides derivatives and use of them for producing pharmaceutical compositions for treating neoplasia
IL116931A (en) Use of N2-¬¬2-¬4-(2-substituted-benzimidazol-L-YL(and imidazo¬4,5-b¾¬pyridin-1-YL)methyl)phenyl¾-cyclohexyl¾-carbonyl¾glycinamide derivatives in the preparation of pharmaceutical compositions for treatment of restenosis certain such novel compounds and their preparation
HUP9901485A3 (en) Heterocyclylcarboxamide derivatives, pharmaceutical compositions containing the same, process for their preparation and their use
HUP0105132A3 (en) Process for preparing imidazo[1,5-a]-pyrido[3,2-e]-pyrazinones and the use of the same for preparing pharmaceutical compositions

Legal Events

Date Code Title Description
FF Patent granted
MM9K Patent not in force due to non-payment of renewal fees